Senior Correspondent, London
Ben's Feed
Nov 25, 2014
Nov 24, 2014

EXCLUSIVE: Pay per puff? Caffeine stick? E-cigarette boom sparks race for new patents

LONDON (Reuters) – Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices.

Research by Thomson Reuters shows that China – with over 300 million smokers – is the front runner in the manufacture and development of so-called e-cigarette technology, while new versions being patented include a “pay as you go” computer-assisted device and others that can deliver caffeine instead.

Nov 24, 2014

Exclusive – Pay per puff? Caffeine stick? E-cigarette boom sparks race for new patents

LONDON (Reuters) – Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices.

Research by Thomson Reuters shows that China – with over 300 million smokers – is the front runner in the manufacture and development of so-called e-cigarette technology, while new versions being patented include a “pay as you go” computer-assisted device and others that can deliver caffeine instead.

Nov 18, 2014
Nov 18, 2014
Nov 18, 2014

AstraZeneca trumpets solo strength in cancer drugs post Pfizer struggle

LONDON (Reuters) – AstraZeneca (AZN.L: Quote, Profile, Research) touted an “industry-leading” line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion (75 billion pound) bid from Pfizer (PFE.N: Quote, Profile, Research) in May.

The company also brought forward the filing date for a new lung cancer pill, and said it could win between eight and 10 new approvals in 2015-2016 for drugs dealing with a wide range of diseases.

Nov 18, 2014
Nov 18, 2014

AstraZeneca trumpets standalone strength in drug development

LONDON (Reuters) – AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

Flagging an “industry-leading” portfolio of immune-boosting cancer drugs, the company also brought forward the filing date for a new lung cancer pill and said it had the potential to win between eight and 10 new drug approvals in 2015-2016 across all disease areas.

Nov 17, 2014
Nov 17, 2014

World’s top drugmaker Novartis takes aim at tech

LONDON (Reuters) – Talent spotters from Novartis AG, charged with bringing new ideas into the organization, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology.

It’s not that the world’s biggest drugmaker by sales wants to make the next smart watch. Rather, its researchers are seeking fresh ways to monitor exactly how the company’s medicines are working and being taken by patients.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben